These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 2035996)

  • 21. [Diagnosis and treatment of localized prostate cancer].
    Usami M; Arai Y
    Hinyokika Kiyo; 1996 Oct; 42(10):759-61. PubMed ID: 8951471
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml.
    Stamey TA; Johnstone IM; McNeal JE; Lu AY; Yemoto CM
    J Urol; 2002 Jan; 167(1):103-11. PubMed ID: 11743285
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A guideline to clinical utility of prostate specific antigen.
    Farhat WA; Habbal AA; Khauli RB
    Saudi Med J; 2000 Mar; 21(3):223-7. PubMed ID: 11533789
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evolving treatment paradigms for locally advanced and metastatic prostate cancer.
    Dorff TB; Quek ML; Daneshmand S; Pinski J
    Expert Rev Anticancer Ther; 2006 Nov; 6(11):1639-51. PubMed ID: 17134367
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prostate cancer Tx. Therapeutic options based on tumor grade, life expectancy, and patient preferences.
    Cohen SP; Jaskulsky SR
    Geriatrics; 2001 Feb; 56(2):39, 42, 47-8 passim. PubMed ID: 11219024
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term results of radical prostatectomy in clinically localized prostate cancer: experience at the Johns Hopkins Hospital.
    Lepor H; Walsh PC
    NCI Monogr; 1988; (7):117-22. PubMed ID: 3173497
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of neoadjuvant androgen deprivation on circulating prostate cells in the bone marrow of men undergoing radical prostatectomy.
    Wood DP; Beaman A; Banerjee M; Powell I; Pontes E; Cher ML
    Clin Cancer Res; 1998 Sep; 4(9):2119-23. PubMed ID: 9748128
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intermediate-term potency, continence, and survival outcomes of radical prostatectomy for clinically high-risk or locally advanced prostate cancer.
    Loeb S; Smith ND; Roehl KA; Catalona WJ
    Urology; 2007 Jun; 69(6):1170-5. PubMed ID: 17572209
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The role of prostate-specific antigen in the diagnosis and treatment of prostatic adenocarcinoma].
    Stamey TA
    Urologe A; 1990 Mar; 29(2):52-64. PubMed ID: 1691883
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Conservative management of prostate cancer in the prostate specific antigen era: the incidence and time course of subsequent therapy.
    Zietman AL; Thakral H; Wilson L; Schellhammer P
    J Urol; 2001 Nov; 166(5):1702-6. PubMed ID: 11586206
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prostate cancer in the senior men from rural areas in east district of China: contemporary management and 5-year outcomes at multi-institutional collaboration.
    Shao Q; Ouyang J; Fan Y; Xie J; Zhou J; Wu J; Karim Kader A; Xu J; Liu G; Shan Y; Wen D; Zhang Y
    Cancer Lett; 2012 Feb; 315(2):170-7. PubMed ID: 22099876
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current results and patient selection for nerve-sparing radical retropubic prostatectomy.
    Steiner MS
    Semin Urol Oncol; 1995 Aug; 13(3):204-14. PubMed ID: 8521134
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Diagnosis and treatment of bladder and prostate cancer in early stages].
    Watanabe H; Nakagawa S; Kojima M
    Nihon Rinsho; 1996 May; 54(5):1405-9. PubMed ID: 8965375
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Localised prostate cancer - current treatment options.
    Duchesne G
    Aust Fam Physician; 2011 Oct; 40(10):768-71. PubMed ID: 22003477
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer.
    D'Amico AV; Hui-Chen M; Renshaw AA; Sussman B; Roehl KA; Catalona WJ
    J Urol; 2006 Dec; 176(6 Pt 2):S11-5. PubMed ID: 17084157
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Quality of life among patients with advanced prostate cancer: a survey using functional assessment of cancer therapy-prostate in China].
    Zhang K; Gong K; Zhou LQ; Na YQ
    Zhonghua Yi Xue Za Zhi; 2008 Mar; 88(10):665-8. PubMed ID: 18642765
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostate cancer: a practical approach to current management of recurrent disease.
    Walczak JR; Carducci MA
    Mayo Clin Proc; 2007 Feb; 82(2):243-9. PubMed ID: 17290734
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A retrospective study of the treatment of locally advanced prostate cancer by six institutions in eastern and north-eastern Japan.
    Hachiya T; Akakura K; Saito S; Shinohara N; Sato K; Harada M; Kato T; Okada K
    BJU Int; 2005 Mar; 95(4):534-40. PubMed ID: 15705075
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnosis, management and screening of early localised prostate cancer.
    Selley S; Donovan J; Faulkner A; Coast J; Gillatt D
    Health Technol Assess; 1997; 1(2):i, 1-96. PubMed ID: 9414541
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Radical prostatectomy with neoadjuvant hormone therapy for cT3 prostate cancer].
    Fujimoto H
    Nihon Rinsho; 2005 Feb; 63(2):271-8. PubMed ID: 15714978
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.